Replies to post #153062 on Biotech Values

[NP1986]

Teva, Gilead settle US patent dispute over generic version of Viread

Teva and Gilead Sciences agreed to settle a US patent dispute over the HIV and chronic hepatitis B therapy Viread (tenofovir), avoiding a trial that was scheduled to start Wednesday, Gilead reported. Under the deal, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

http://www.firstwordpharma.com/node/1059686